BriaCell Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is August - July.

Millions USD. Fiscal year is Aug - Jul.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	21.25	41.04	57.27	0.02	0.12
Cash & Cash Equivalents	21.25	41.04	57.27	0.02	0.12
Cash Growth	-48.22%	-28.33%	349910.30%	-86.47%	-
Receivables	0.02	0.02	0.01	0.02	0
Other Current Assets	5.68	1.28	0.52	0.17	0.01
Total Current Assets	26.95	42.35	57.8	0.2	0.13
Long-Term Investments	0	0	0	0	0
Goodwill and Intangibles	0.22	0.23	0.25	0.2	0.21
Other Long-Term Assets	0	0	0	-0	0
Total Long-Term Assets	0.22	0.23	0.25	0.2	0.21
Total Assets	27.16	42.58	58.04	0.4	0.34
Accounts Payable	1.12	0.46	0.21	2.86	0.62
Current Debt	0	0	0	0.19	0.25
Other Current Liabilities	0.68	0.48	0.34	0	0
Total Current Liabilities	1.8	0.94	0.56	3.05	0.87
Long-Term Debt	0	0	0.03	0.12	0
Other Long-Term Liabilities	29.14	31.31	29.79	0	0
Total Long-Term Liabilities	29.14	31.31	29.82	0.12	0
Total Liabilities	30.94	32.25	30.37	3.17	0.87
Total Debt	0	0	0.03	0.31	0.25
Debt Growth	-	-	-91.68%	25.80%	-
Retained Earnings	-80.65	-60.35	-29.14	-13.99	-11.35
Comprehensive Income	-0.14	-0.14	-0.14	-0.11	-0.08
Shareholders' Equity	-3.78	10.33	27.67	-2.77	-0.53
Net Cash / Debt	21.25	41.04	57.24	-0.3	-0.13
Net Cash / Debt Growth	-48.22%	-28.30%	-	-	-
Net Cash Per Share	1.36	2.65	12.67	-0.41	-0.22
Working Capital	25.15	41.41	57.24	-2.85	-0.74
Book Value Per Share	-0.24	0.67	6.12	-3.88	-0.92

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).